| Document |
Document Title |
|
WO/2007/004090A2 |
The present invention relates to processes for the prepartion of purified solanesol, solanesyl bromide & solanesyl acetone. Solanesyl acetone has the chemical name - all - trans 6, 10, 14, 18, 22, 26, 30, 34, 38 -nonamethyl -5,9, 13, 17,...
|
|
WO/2006/062129A1 |
A process for producing (5&agr ,7&agr )-3-spiro-2'-(1',3'-dioxolan)-24-oxocholest-22-en-7-yl benzoate (unsaturated ketone (I)), which is represented by the formula (I), (I) characterized by dissolving in methanol a crude reaction product...
|
|
WO/2006/052263A1 |
Methods for separation and synthesis of the optically active 7-thioester isomers and mono or bis-cyclopropyl derivatives of spironolactone are provided. Preferred stereoisomerically purified 7-thioester isomers and mono or bis-cyclopropy...
|
|
WO/2006/045745A1 |
A process is described for preparing, exclusively by chemical way, 21-hydroxy steroids having progestinic activity, said process having a high stereochemical control at C-21 position.
|
|
WO/2006/032970A2 |
Processes are described for the conversion of a steroid substrate having a 4,7-carbonyl bridge to a structure comprising a 7&agr -alkoxycarbonyl substituent by reaction of the substrate with an alkoxy group source, preferably in the pres...
|
|
WO/2005/092913A1 |
Processes are described for epoxidation reactions. In particular, the process comprises the conversion of a steroid substrate having an olefinic unsaturation in the steroid nucleus to a structure comprising a 9,11-epoxy substituent by re...
|
|
WO/2004/089304A2 |
The instant invention provides potent antiandrogen compounds, such as 3β -acetoxyandrost-1,5-diene-17-ethylene ketal and 3β-hydroxyandrost-1, 5-diene-17ethylene ketal, and methods for their use in the prevention and treatment of biolog...
|
|
WO/2004/078709A2 |
Methods for the preparation of the 19-norprogesterone of formula I and its intermediates, in crystalline and amorphous forms.
|
|
WO/2004/043987A1 |
This invention relates to processes for the preparation of 7-carboxy substituted steroid compounds of Formula (I) wherein R1 is selected from H or COR4; R4 is C1-C6 alkyl or C1-C6 alkoxy; R3 is C1-C6 alkyl; Z1 is -CH2- or Formula (II) wh...
|
|
WO/2004/043986A1 |
This invention relates to processes for the preparation of novel , substituted steroid compounds of Formula 1, wherein R1 is H or. COR2; R2 is C1-C6 alkyl or Ct-C6 alkoxy; Z1 is CH2, or wherein OR3 is in the &agr configuration; R3 is H o...
|
|
WO/2004/037843A2 |
The present invention relates to multifunctional steroid compounds combining a steroid component with SOD mimic component and optionally also with NO donor component, and to their use in treating and preventing disorders associated with ...
|
|
WO/2004/037844A1 |
The present invention involves a novel crystal form of 17β-hydroxy-7&agr -(5'-methyl-2'-furyl)-pregna-4,9(11)-dien-3-one-21-carboxyli
c acid, &gammad -lactone (II) which is an intermediate useful in preparation of an important pharmaceu...
|
|
WO/2004/031204A2 |
The present invention is a process for the preparation of l7ß-hydroxy-7&agr -methyl-19-nor-17&agr -pregn-5(10)-en-20-yn-3-one (17&agr -ethynyl-l7ß-hydroxy-7&agr -methyl-5(10)-estren-3-one, tibolone) of formula 1, which comprises hydrol...
|
|
WO/2004/016640A2 |
The present invention provides 5-androsten-3β-ol steroid intermediates and processes for their preparation.
|
|
WO/2004/014934A2 |
The present invention relates to a new process of synthesis and to some new intermediates for the preparation of steroids with progestogen activity, more particularly, for the preparation of Desogestrel of formula (I). Said process is ch...
|
|
WO/2004/007370A1 |
A process for producing a raw material for the formation of proton-exchanged zeolite analogues whose cations are wholly or partially exchanged by H+ and which contain zeolite having tektosilicate structure, characterized by the step of t...
|
|
WO/2004/005310A2 |
The present invention relates (a) to new compounds represented by Formula (I): wherein M represents a macrolide subunit (macrolide moiety) derived from macrolide possessing the property of accumulation in inflammatory cells, S represents...
|
|
WO/2003/082894A2 |
Novel processes for the C-17 spirolactonization and 6,7 oxidation of steroid compounds are provided. In certain preferred embodiments, the present invention provides for the preparation of steroid compounds which are useful in the prepar...
|
|
WO/2003/082895A2 |
The present invention involves novel intermediates, including a 7&agr -substituted steriod (II), and various novel processes which are used to prepare known intermediates useful in the production of eplerenone, a pharmaceutical agent.
|
|
WO/2003/075015A2 |
The invention relates to a method of screening cellular polypeptides for pro-apoptotic or anti-apoptotic activity in a cell of a particular cell-type, said method comprising a. culturing cells of said particular cell-type under non apopt...
|
|
WO2002009760A9 |
A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory di...
|
|
WO/2003/068736A2 |
Disclosed herein are mixed steroidal tetraoxanes having the following structural Formula (I), wherein n is 0, 1, 2, or 3; R is H; ethanoyl, propanoyl, or benzoyl; R1 is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or ethyl; R3 is H, ...
|
|
WO2002009683A9 |
Aldosterone blockers used for the treatment and prevention of inflammation are disclosed.
|
|
WO/2003/006027A1 |
A pharmaceutical dosage unit comprising drospirenone and an estrogen sulphamate, such as an estradiol sulphamate or an estriol sulphamate for use in hormone replacement therapy is disclosed. This, combination therapy may comprise continu...
|
|
WO/2002/102391A2 |
The invention relates to nanoparticles comprising spironolactone. The nanoparticles have a mean diameter, measured by photon correlation spectroscopy, in the range of from about 300nm to about 900nm.
|
|
WO/2002/100880A1 |
The invention concerns a method for preparing compounds of formula (I) wherein: R¿1?, R¿2?, R¿3? and n are such as defined in the description, the use of said compounds as intermediates for preparing oestrogen derivatives and the inte...
|
|
WO/2002/094849A2 |
Steroids containing a cyclohexene moiety are efficiently oxidized to the corresponding &agr , β−unsaturated ketone using copper iodide and t−butyl hydroperoxide. A steroid compound containing the &agr , β−unsaturated ketone struc...
|
|
WO/2002/069977A1 |
The invention relates to the use of compounds to treat a number of conditions, such as thrombocytopenia, neutropenia or the delayed effects of radiation therapy. Compounds that can be used in the invention include methyl-2,3,4-trihydroxy...
|
|
WO/2002/038582A2 |
The invention relates to a method for the production of 4-(17$g(a) substituted 3-oxoestra-4,9-dien-11$g(b)-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R¿1? = H, C¿1-6? alkyl or a C¿n?F¿2n+1? group; R¿2? = C¿1-4? ...
|
|
WO/2002/038581A2 |
The invention relates to a method for the production of 4-(17$g(a)-methyl substituted 3-oxoestra-4,9-dien-11$g(b)-yl)benzaldehyd-(1E or 1Z)-oximes of general formula (I), where R¿1? = H, C¿1-6? alkyl or a C¿n?F¿2n+1? group, where n =...
|
|
WO/2002/036606A1 |
This invention is directed to a method for treating an inflammatory condition, treating haematological and other malignancies, causing immunosuppression, or preventing or treating transplant rejection in man or other animals which compri...
|
|
WO/2002/024715A2 |
The present invention provides compositions comprising at least one GHB moiety bonded to at least one physiologically compatible carrier molecule. The compositions can enhance the uptake of the drug, deliver effective therapeutic doses i...
|
|
WO/2002/020552A1 |
A process for the preparation of pregnane derivatives which comprises reacting a compound (I) with an alkali metal or an alkaline earth metal in the presence of ammonia or an amine to obtain a compound (II), protecting the hydroxyl group...
|
|
WO/2002/017895A2 |
Aldosterone receptor antagonists for the prevention and treatment of cognitive dysfunction are disclosed.
|
|
WO/2002/009759A2 |
Combinations of aldosterone blockers an Cyclooxygenase-2 inhibitors useful in the treatment of inflammation are disclosed.
|
|
WO/2001/087284A2 |
A pharmaceutical composition is provided for administration to a subject mammal such as a human exhibiting a diurnal cycle of plasma aldosterone concentration, the composition comprising a delayed-release formulation of an aldosterone an...
|
|
WO/2001/079255A1 |
An efficient method for the synthesis of aminosterol compounds such as squalamine and compound 1436 is described. A method of the invention provides for regioselective oxidation and regioselective sulfonation of a fused ring system. The ...
|
|
WO/2001/074839A2 |
Methods of using 7$g(a),11$g(b)-dimethyl-17$g(b)-hydroxy-4-estren-3-one bucyclate (I) and 7$g(a),11$g(b)-dimethyl-17$g(b)-hydroxyestr-4-en-3-one 17-undecanoate (II) for various hormonal therapies, dosage forms comprising 7$g(a),11$g(b)-d...
|
|
WO/2001/072293A2 |
The present invention features methods of inhibiting progestin activity in a cell or in a subject in need of such inhibition, and methods of treating or preventing progestin-dependent conditions in a subject in need of such treatment or ...
|
|
WO/2001/047945A1 |
The present invention provides a process for preparing the antiprogestational agent, 17$g(a)-acetoxy-11$g(b)-[4-N,N-(dimethylamino)phenyl]-21-met
hoxy-19-norpregna-4,9-diene-3,20-dione, intermediates useful in the process, and processes ...
|
|
WO/2000/031112A1 |
Disclosed is a novel class of steroid compounds based on estradiol, and carrying an 11$g(b)- substitution. Said substitution is a hydrocarbon group which may be linear or branched, provided that it comprises, as the longest chain on carb...
|
|
WO/2000/007576A2 |
Novel methods of treating and/or inhibiting development of prostatic cancer, benign prostatic hyperplasia, prostatitis, acne, seborrhea, hirsutism or androgenic alopecia utilize inhibitors of type 3 3$g(a)-hydroxysteroid dehydrogenase al...
|
|
WO/1999/062928A1 |
The invention is directed to a novel class of steroids which exhibit potent antiprogestational activity.
|
|
WO/1999/058549A1 |
Certain novel sterol derivatives can be used for regulating the meiosis in oocytes and in male germ cells.
|
|
WO/1999/046279A2 |
Novel methods of medical treatment and/or inhibition of development of diseases are disclosed for diseases that are sensitive to androgenic or estrogenic activity. The treatments utilize inhibitors of type 5 and/or type 3 17$g(b)-hydroxy...
|
|
WO/1999/025725A1 |
The invention concerns compounds of formula (I) in which: X is a halogen atom; D represents the radical of a pentagonal or hexagonal cycle optionally substituted and optionally unsaturated; R¿1?, R¿2?, R¿3?, R¿4?, X and n are as defi...
|
|
WO/1998/045315A1 |
This invention provides estra-5(10),7-dien-3$g(b)-ol-17-one or a pharmaceutically acceptable salt of its 3-sulfate ester, estra-5(10),7-dien-3$g(b)-ol-17-one 3-glucuronide or a pharmaceutically acceptable salt thereof, estra-5(10),7-dien...
|
|
WO/1998/031702A1 |
The present invention relates to 16-hydroxy-11-(substituted phenyl)-estra-4,9-diene derivatives according to formula (I), wherein R�1? is C�1-6?alkyl, C�3-6?cycloalkyl, C�1-6?alkoxy, triflate, pyridyl or phenyl where the phenyl m...
|
|
WO/1998/025948A2 |
Multiple novel reaction schemes, novel process steps and novel intermediates are provided for the synthesis of epoxymexrenone and other compounds of formula (I) wherein: -A-A- represents the group -CHR?4�-CHR?5�- or -CR?4�=CR?5�-...
|
|
WO/1998/014194A1 |
The invention relates to a method of alleviating the symptoms of anxiety. The method comprises nasally administering a steroid which is a human vomeropherin, such that the vomeropherin binds to a specific neuroepithelial receptor. The st...
|
